Aptose Biosciences Rises; HC Wainwright Sees Inflection Point
Alert: HALISTER1
Source: BFW (Bloomberg First Word)
Tickers
APS CN (Aptose Biosciences Inc)
To de-activate this alert, click here
To modify this alert, click here
UUID: 7947283
(Bloomberg) -- Aptose Biosciences rises 8% pre-market on 2.6k volume after HC Wainwright upgraded to buy from neutral, PT $4 from $1.
- Says co. made progress on the manufacturing process for CG’806 and is targeting the initiation of toxicology studies shortly
- Says an IND filing is targeted for 1H 2018, assuming clean toxicology studies, with the initiation of the clinical programs soon after that
- Notes the Ash conf. in December should provide more visibility on CG’806
- NOTE: Jan. 23, Aptose Pauses APTO-253 Development, Will Prioritize CG’806
Alert: HALISTER1
Source: BFW (Bloomberg First Word)
Tickers
APS CN (Aptose Biosciences Inc)
To de-activate this alert, click here
To modify this alert, click here
UUID: 7947283